MDM2 and glioblastoma: Recently, Nutlin-3, the first potent MDM2 small-molecule inhibitor identified [23], and new D-peptide derivatives [14], [24] were reported to be effective at inhibiting GBM cell growth in vitro[14], [24], [25], suggesting the validity of this experimental approach for the treatment of GBM.